Combining this with the study that found TSH can promote the growth of melanoma by triggering the formation of cAMP and activating the mitogen-activated protein kinase (MAPK) signaling pathway, may in part account for the high prevalence of hypothyroidism (elevated TSH lever) in the melanoma population [48,49]. Here, WNK2 is linked to melanoma.